Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12711157 | 0.82 | ADRB2 (0.38) | ALDH1A1MAPT | |
| SCHEMBL12711161 | 0.80 | NR3C2 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL12711160 | 0.79 | HTT (0.38) | CYP2C9ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL12711154 | 0.79 | CYP3A4 (0.37) | ALDH1A1CYP3A4 | |
| SCHEMBL12711162 | 0.78 | ACP3 (0.37) | CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12711151 | 0.75 | TRPA1 (0.45) | KDM4EALDH1A1MAPT | |
| SCHEMBL12711171 | 0.75 | TRPA1 (0.45) | KDM4EALDH1A1MAPT | |
| SCHEMBL12696868 | 0.69 | NPSR1 (0.31) | — | |
| SCHEMBL12711158 | 0.67 | HDAC4 (0.38) | — | |
| SCHEMBL12711121 | 0.66 | SRC (0.40) | ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | CYP2C9 3753/4885KDM4E 2956/4885ALDH1A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.